Ideaya Biosciences (IDYA) announced they have enrolled their first patient with non-small cell lung cancer in the ongoing Phase 1/2 combination trial of IDE397, a small molecule adenosyltransferase 2a inhibitor, and Trodelvy, a Trop2-directed antibody-drug conjugate, in patients with methylthioadenosine phosphorylase-deletion solid tumors. Ideaya is conducting the trial pursuant to a clinical study collaboration and supply agreement with Gilead (GILD), where the initial focus was in MTAP-deletion urothelial cancer. In April, the companies announced expansion of the combination trial into MTAP-deletion NSCLC.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences initiated with an Outperform at Citizens JMP
- Ideaya Biosciences initiated with an Overweight at Barclays
- Hold Rating for IDEAYA Biosciences Amid Favorable Financial Terms and Developmental Risks
- Ideaya Biosciences price target raised to $74 from $72 at JPMorgan
- Ideaya Biosciences submits IDE892 IND application to FDA